The europe opioid use disorder treatment market is poised for substantial growth, projected to reach USD 131.3 million by 2025, expanding at a 5.8% CAGR from 2025 to 2035. This growth is primarily ...

A groundbreaking study from TrimBody MD has revealed that semaglutide, a GLP-1 agonist originally designed for diabetes and ...